Live Attenuated Vaccines for Invasive Salmonella Infections

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2015 Apr 23

PMID 25902362

Citations 43

Authors

Sharon M Tennant

Myron M Levine

Affiliations

Soon will be listed here.

Abstract

Salmonella enterica serovar Typhi produces significant morbidity and mortality worldwide despite the fact that there are licensed Salmonella Typhi vaccines available. This is primarily due to the fact that these vaccines are not used in the countries that most need them. There is growing recognition that an effective invasive Salmonella vaccine formulation must also prevent infection due to other Salmonella serovars. We anticipate that a multivalent vaccine that targets the following serovars will be needed to control invasive Salmonella infections worldwide: Salmonella Typhi, Salmonella Paratyphi A, Salmonella Paratyphi B (currently uncommon but may become dominant again), Salmonella Typhimurium, Salmonella Enteritidis and Salmonella Choleraesuis (as well as other Group C Salmonella). Live attenuated vaccines are an attractive vaccine formulation for use in developing as well as developed countries. Here, we describe the methods of attenuation that have been used to date to create live attenuated Salmonella vaccines and provide an update on the progress that has been made on these vaccines.

Citing Articles

Characterization and Protective Efficacy of a ATCC 14028 Mutant as a Live Attenuated Vaccine Candidate.

Zhou N, Ding Y, He T, Sun Y, Chen H, Huang M Vaccines (Basel). 2025; 13(2).

PMID: 40006697 PMC: 11860608. DOI: 10.3390/vaccines13020150.

Combatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination.

Nazir J, Manzoor T, Saleem A, Gani U, Bhat S, Khan S BMC Infect Dis. 2025; 25(1):84.

PMID: 39833704 PMC: 11744889. DOI: 10.1186/s12879-025-10478-5.

Recombinant Live-Attenuated Vaccine for Veterinary Use.

Chagas D, Santos F, de Oliveira N, Bohn T, Dellagostin O Vaccines (Basel). 2025; 12(12.

PMID: 39771981 PMC: 11680399. DOI: 10.3390/vaccines12121319.

Deletion of both anaerobic regulator genes fnr and narL compromises the colonization of Salmonella Typhimurium in mice model.

Priyadarsini S, Mani P, Singh R, Nikhil K, Sahoo P, Kesavan M World J Microbiol Biotechnol. 2024; 40(12):373.

PMID: 39487264 DOI: 10.1007/s11274-024-04179-5.

From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.

Kajal , Pandey A, Mishra S 3 Biotech. 2024; 14(10):242.

PMID: 39319014 PMC: 11417089. DOI: 10.1007/s13205-024-04075-7.

References

Wood M, Jones M, Watson P, Hedges S, Wallis T, Galyov E . Identification of a pathogenicity island required for Salmonella enteropathogenicity. Mol Microbiol. 1998; 29(3):883-91. DOI: 10.1046/j.1365-2958.1998.00984.x. View

MacLennan C, Martin L, Micoli F . Vaccines against invasive Salmonella disease: current status and future directions. Hum Vaccin Immunother. 2014; 10(6):1478-93. PMC: 4185946. DOI: 10.4161/hv.29054. View

Ochman H, Soncini F, Solomon F, Groisman E . Identification of a pathogenicity island required for Salmonella survival in host cells. Proc Natl Acad Sci U S A. 1996; 93(15):7800-4. PMC: 38828. DOI: 10.1073/pnas.93.15.7800. View

Mukkur T, Stocker B, Walker K . Genetic manipulation of Salmonella serotype Bovismorbificans to aromatic-dependence and evaluation of its vaccine potential in mice. J Med Microbiol. 1991; 34(1):57-62. DOI: 10.1099/00222615-34-1-57. View

Wain J, Hendriksen R, Mikoleit M, Keddy K, Ochiai R . Typhoid fever. Lancet. 2014; 385(9973):1136-45. PMC: 11567078. DOI: 10.1016/S0140-6736(13)62708-7. View

Levine M, Ferreccio C, Cryz S, Ortiz E . Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990; 336(8720):891-4. DOI: 10.1016/0140-6736(90)92266-k. View

Alper M, Ames B . Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol. 1978; 133(1):149-57. PMC: 221988. DOI: 10.1128/jb.133.1.149-157.1978. View

Kelly S, Bosecker B, Curtiss 3rd R . Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect Immun. 1992; 60(11):4881-90. PMC: 258244. DOI: 10.1128/iai.60.11.4881-4890.1992. View

Garcia-del Portillo F, Pucciarelli M, Casadesus J . DNA adenine methylase mutants of Salmonella typhimurium show defects in protein secretion, cell invasion, and M cell cytotoxicity. Proc Natl Acad Sci U S A. 1999; 96(20):11578-83. PMC: 18076. DOI: 10.1073/pnas.96.20.11578. View

10.

Galan J, Curtiss 3rd R . Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog. 1989; 6(6):433-43. DOI: 10.1016/0882-4010(89)90085-5. View

11.

Song M, Kim H, Kim E, Shin M, Lee H, Hong Y . ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem. 2004; 279(33):34183-90. DOI: 10.1074/jbc.M313491200. View

12.

Tomoyasu T, Takaya A, Isogai E, Yamamoto T . Turnover of FlhD and FlhC, master regulator proteins for Salmonella flagellum biogenesis, by the ATP-dependent ClpXP protease. Mol Microbiol. 2003; 48(2):443-52. DOI: 10.1046/j.1365-2958.2003.03437.x. View

13.

Dueger E, House J, Heithoff D, Mahan M . Salmonella DNA adenine methylase mutants elicit protective immune responses to homologous and heterologous serovars in chickens. Infect Immun. 2001; 69(12):7950-4. PMC: 98898. DOI: 10.1128/IAI.69.12.7950-7954.2001. View

14.

Galen J, Curtiss 3rd R . The delicate balance in genetically engineering live vaccines. Vaccine. 2013; 32(35):4376-4385. PMC: 4069233. DOI: 10.1016/j.vaccine.2013.12.026. View

15.

Wahid R, Zafar S, McArthur M, Pasetti M, Levine M, Sztein M . Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol. 2014; 21(3):427-34. PMC: 3957674. DOI: 10.1128/CVI.00786-13. View

16.

Germanier R, Fuer E . Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975; 131(5):553-8. DOI: 10.1093/infdis/131.5.553. View

17.

Simon R, Tennant S, Wang J, Schmidlein P, Lees A, Ernst R . Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun. 2011; 79(10):4240-9. PMC: 3187246. DOI: 10.1128/IAI.05484-11. View

18.

Tacket C, Hone D, Curtiss 3rd R, Kelly S, Losonsky G, Guers L . Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun. 1992; 60(2):536-41. PMC: 257661. DOI: 10.1128/iai.60.2.536-541.1992. View

19.

COYNAULT C, Norel F . Comparison of the abilities of Salmonella typhimurium rpoS, aroA and rpoS aroA strains to elicit humoral immune responses in BALB/c mice and to cause lethal infection in athymic BALB/c mice. Microb Pathog. 1999; 26(6):299-305. DOI: 10.1006/mpat.1999.0273. View

20.

Kingsley R, Msefula C, Thomson N, Kariuki S, Holt K, Gordon M . Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res. 2009; 19(12):2279-87. PMC: 2792184. DOI: 10.1101/gr.091017.109. View